Table 2. Summary of lymphocytic infiltration in tumor tissues (under 20×object lens).
| Group (vaccine) |
Rabbit ID | Approximate cell numbers | Outcome (histology) |
|
|---|---|---|---|---|
| Tumor site 1 | Tumor site 2 | |||
| Group 1 (TT-E1 peptide) |
3206 | -(9) | +(40) | Persistent |
| 3219 | - (10) | - (8) | Persistent | |
| 2914 | +(30) | +(30) | Persistent | |
| 3214 | - (4) | +(50) | Persistent | |
| Group 2 (E1 peptide) |
3207 | - (8) | - (8) | Persistent |
| 3222 | +(47) | - (5) | Persistent | |
| 2916 | - (9) | +(30) | Persistent | |
| 3216 | - (8) | +(35) | Persistent | |
| Group 3 (E1 peptide-TT) |
3210 | - (8) | +(30) | Persistent |
| 3223 | +(>100) | NA | Small tumor | |
| 2917 | NA | NA | Regressed | |
| 3217 | - | +(20) | Persistent | |
| Group 4 (TT-control) |
3211 | - (10) | - (5) | Early cancer* |
| 3224 | - (9) | - (6) | Early cancer | |
| 2918 | - (10) | - (4) | Persistent | |
| 3218 | +(20) | - (1) | Persistent | |